Irreversible electroporation promising in pancreatic cancer

September 4, 2015
Irreversible electroporation promising in pancreatic cancer

(HealthDay)—Irreversible electroporation (IRE) in pancreatic cancer cells may improve survival rates for some patients, new research suggests. The findings were published in the September issue of the Annals of Surgery.

Robert Martin II, M.D., Ph.D., director of at the University of Louisville in Kentucky, and colleagues included patients with locally-advanced pancreatic cancer, making complete surgical removal impossible. All of the 200 adults with stage III pancreatic cancer included in the current study underwent electrical IRE treatment after completing chemotherapy.

About half of the patients in the study experienced complications. But the side effects related to IRE were minimal, according to Martin. Any side effects were "directly related to the surgical procedure" required to make the tumor area accessible, he told HealthDay. The average survival was two years. The study authors followed some patients for as long as seven years.

"For patients with locally-advanced (stage III), the addition of IRE to conventional chemotherapy and radiation therapy results in substantially prolonged survival compared with historical controls," the authors write. "These results suggest that ablative control of the primary tumor may prolong survival."

Explore further: CT-guided irreversible electroporation safe in unresectable pancreatic carcinoma

More information: Full Text (subscription or payment may be required)

Related Stories

CT-guided irreversible electroporation safe in unresectable pancreatic carcinoma

May 7, 2014
A small group of patients with locally advanced unresectable pancreatic carcinoma suffered no major ill effects—pancreatitis or fistula formation—after undergoing percutaneous CT-guided irreversible electroporation (IRE)—a ...

Study finds genes associated with improved survival for pancreatic cancer patients

August 20, 2015
A study by the Translational Genomics Research Institute (TGen) and other major research institutes, found a new set of genes that can indicate improved survival after surgery for patients with pancreatic cancer. The study ...

Electrical pulse treatment gives pancreatic cancer patients new hope

March 26, 2012
Results of a study presented at the Society of Interventional Radiology's 37th Annual Scientific Meeting in San Francisco, Calif., signal a light at the end of the tunnel for individuals with inoperable locally advanced pancreatic ...

Chemotherapy and SABR consecutively may be promising treatment option for advanced pancreatic cancer

September 16, 2014
For patients with locally advanced pancreatic cancer, the combination of chemotherapy and stereotactic ablative radiation (SABR) may be a promising treatment option, ultimately allowing them to undergo surgery that may not ...

Stereotactic body radiation therapy appears to help some patients with pancreatic cancer

May 18, 2015
Two studies from Johns Hopkins Kimmel Cancer Center researchers add to preliminary evidence that high-dose radiation treatment, called stereotactic body radiotherapy, appears to be safe and as effective as standard radiation ...

Intraperitoneal chemotherapy ups ovarian cancer outcomes

August 5, 2015
(HealthDay)—Intraperitoneal chemotherapy significantly improves survival among women with advanced ovarian cancer; however, fewer than half of eligible U.S. patients are receiving it, according to research published online ...

Recommended for you

New drug candidate makes cancer cells more sensitive to radiotherapy

September 26, 2018
Researchers from Karolinska Institutet and Kancera AB have developed a molecule that makes cancer cells sensitive to radiotherapy. In a study published in Nature Communications, the researchers describe a new way to block ...

Aspirin could play valuable role as additional treatment for cancer

September 26, 2018
Regular use of aspirin could help in the treatment of some cancers, finds a new review of 71 medical studies.

Lung cancer drug could be repurposed to target 'zombie' proteins linked to leukemia

September 25, 2018
A new study by scientists at the University of Liverpool highlights how a clinically-approved lung cancer drug could potentially be 'repurposed' to design new treatments for future cancer therapies.

Combo therapy of prostatectomy plus radiotherapy may improve survival in prostate cancer

September 25, 2018
High-risk prostate cancer, that which has continued to grow but not yet metastasized, is commonly treated with combination therapies. Each method has pros and cons, but there is little clarity whether one might be more effective ...

Brigatinib becomes potential new first-line option for ALK-positive non-small lung cancer

September 25, 2018
Results of a 275-patient, multi-national phase III clinical trial known as ALTA-1L published today in the New England Journal of Medicine and presented concurrently in the press program at the International Association for ...

Two studies describe improved approach to bone marrow transplant

September 25, 2018
Two recent studies in the journal Leukemia present a new approach for bone marrow donation and transplant that preclinical laboratory tests suggest could make the life-saving procedure safer and more effective for patients.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.